Evidence map›Paper›PMID 39651075›Full record

ArticleACS omega2024

Quercetin and Astragaloside IV Mitigate the Developmental Abnormalities Induced by Gestational Exposure to Zinc Oxide Nanoparticles.

Li Ji, Qiuru Huang, Yujuan Qi, Zihan Wang, Xiuwen Kong, Xiaoqi Zhu, Binbin Yang, Jiaxin Li, Xuxin He, Xiaonan Deng and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Li JiInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Qiuru HuangInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Yujuan QiClinical Center of Reproductive Medicine, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical University, Xuzhou 221000, China.
Zihan WangInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Xiuwen KongInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Xiaoqi ZhuInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Binbin YangInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Jiaxin LiInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Xuxin HeInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Xiaonan DengInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Xinmeng ChengInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Hao YuInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Yi ShiInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Ziwen LinInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.
Xinyuan ZhaoDepartment of Occupational Medicine and Environmental Toxicology, Nantong Key Laboratory of Environmental Toxicology, School of Public Health, Nantong University, Nantong 226019, China.ORCID https://orcid.org/0000-0002-7317-8016
Xiaorong WangCenter for Reproductive Medicine, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong 226018, China.
Jun YuInstitute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226001, China.ORCID https://orcid.org/0000-0003-3109-4102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zinc oxide (ZnO) nanoparticles (NPs) are extensively utilized in the commercial and biomedical sectors, posing heightened risks of potential cytotoxicity through various mechanisms. Nonetheless, the regulatory framework governing the gestational toxicity of ZnO NPs and the corresponding intervention strategies remain largely obscure. In this study, using the

Identifiers

PMID39651075
PMCPMC11618501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.